ERR2598080
fetal · fetal
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- fetal
- cancer_type_detailed
- —
- subtype
- fetal
- cancer_type
- fetal
- subtype
- fetal
- sex
- fetal
- race
- fetal
- fetal_age_hindbrain
- 11
- umap1_2d
- -3.595960978
- umap2_2d
- 3.933736936
- umap1_3d
- -1.678162267
- umap2_3d
- 2.140656719
- umap3_3d
- -1.094226682
- dataset
- fetal
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.280
- ESTROGEN_RESPONSE_EARLY+0.260
- UV_RESPONSE_DN+0.260
- HEME_METABOLISM+0.230
- HEDGEHOG_SIGNALING+0.210
- PEROXISOME+0.200
- PANCREAS_BETA_CELLS+0.180
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.150
- BILE_ACID_METABOLISM+0.140
- APICAL_JUNCTION+0.110
Top 10 suppressed
- E2F_TARGETS-0.410
- MYC_TARGETS_V1-0.370
- G2M_CHECKPOINT-0.330
- DNA_REPAIR-0.310
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- MYC_TARGETS_V2-0.280
- UNFOLDED_PROTEIN_RESPONSE-0.250
- HYPOXIA-0.230
- INTERFERON_ALPHA_RESPONSE-0.210
- MITOTIC_SPINDLE-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ERR2598126 | fetal | fetal | 0.840 |
| 2 | TCGA-GD-A3OP-01A-21R-A220-07 | — | — | 0.806 |
| 3 | SRR25043630 | — | — | 0.802 |
| 4 | MNG942 | — | — | 0.800 |
| 5 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.792 |
| 6 | 65f86d9a-828b-4e8b-a656-38baba5a54f7 | — | — | 0.780 |
| 7 | MDT-AP-3326 | Med | Medulloblastoma | 0.779 |
| 8 | TCGA-CR-7389-01A-11R-2016-07 | — | — | 0.778 |
| 9 | BS_A14Z8BBK | Med | Medulloblastoma | 0.768 |
| 10 | TCGA-50-5942-01A-21R-1755-07 | — | cohortA1 | 0.761 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.260 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.230 | Temsirolimus | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.090 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.040 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.040 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.030 | Inavolisib | — uncovered |